Anna Rea

Anna Rea

Auto-generated profile, based on publicly available information

Anna Rea

Department of Medicine and Life Sciences Universitat Pompeu Fabra Barcelona Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Blood
Verified
Journal Article
Open access
PDF file
RERosaura Esteve-Puig
Rosaura Esteve-Puig
FCFina Climent
Fina Climent
DPDavid Piñeyro
David Piñeyro
EDEva Domingo-Domenech
Eva Domingo-Domenech
VDVerónica Dávalos
Verónica Dávalos
MEManel Esteller
Manel Esteller

1 December 2021 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MCMariona Cabo
Mariona Cabo
SSSara Santana-Hernández
Sara Santana-Hernández
MCMarcel Costa-Garcia
Marcel Costa-Garcia
ARAnna Rea
Anna Rea
RLRoberto Lozano-Rodríguez
Roberto Lozano-Rodríguez
AMAura Muntasell
Aura Muntasell
Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and functional analyses showed that CD137 costimulation modified the transcriptional program induced by TGFβ on human NK cells by rescuing their proliferation in response to IL2, preserving their expression of activating receptors (NKG2D) and effector molecules (granzyme B, IFNγ) while allowing the acquisition of tumor-homing/retention features (CXCR3, CD103). Activated NK cells cultured in the presence of TGFβ1 and CD137 agonist recovered CCL5 and IFNγ secretion and showed enhanced direct and antibody-dependent cytotoxicity upon restimulation with cancer cells. Trastuzumab treatment of fresh breast carcinoma–derived multicellular cultures induced CD137 expression on tumor-infiltrating CD16+ NK cells, enabling the action of urelumab, which fostered tumor-infiltrating NK cells and recapitulated the enhancement of CCL5 and IFNγ production. Bioinformatic analysis pointed to IFNG as the driver of the association between NK cells and clinical response to trastuzumab in patients with HER2-positive primary breast cancer, highlighting the translational relevance of the CD137 costimulatory axis for enhancing IFNγ production. Our data reveals CD137 as a targetable checkpoint for overturning TGFβ constraints on NK-cell antitumor responses.

15 May 2022 in HLA
Verified
Journal Article
Open access
RMRaffaella Meazza
Raffaella Meazza
MFMichela Falco
Michela Falco
PCPaolo Canevali
Paolo Canevali
FLFabrizio Loiacono
Fabrizio Loiacono
NCNatalia Colomar‐Carando
Natalia Colomar‐Carando
Daniela PendeDaniela Pende
Daniela Pende
The phenotypic identification of different NK cell subsets allows more in‐depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. KIR genes are highly polymorphic, but a great homology exists among the various sequences and few monoclonal antibodies (mAbs) specifically recognize a single KIR. This is the case of HP‐DM1 which was demonstrated by analysis of cell transfectants and epitope mapping to be exclusively KIR2DL1‐specific, covering all allotypes identified to date, except for KIR2DL1*022 and *020, and also to react with KIR2DS1*013. Here, we compared in immunofluorescence analyses the staining of HP‐DM1 with other available mAbs to precisely identify KIR2DL1+ NK cells in potential donors for αβT/B‐depleted haplo‐HSCT, with known KIR genotype. HP‐DM1 mAb was used in combination with EB6 or 11PB6 (anti‐KIR2DL1/S1 and anti‐KIR2DL3*005), 143211 (anti‐KIR2DL1/S5), and HP‐MA4 (anti‐KIR2DL1/S1/S3/S5) mAbs, allowing the accurate identification of different KIR+ NK cell subsets. These phenotypic evaluations appeared useful to dissect the expression pattern of various KIR2D in NK cells from KIR2DL3*005+ individuals, particularly if KIR2DS1 is present. HP‐DM1 mAb remarkably refined NK cell phenotyping of donors carrying KIR2DS5, either in the centromeric or telomeric region. Functional assays with KIR2DL1+/S1+/S5+ NK cells confirmed that only HP‐DM1 exclusively reacts with KIR2DL1. Finally, we demonstrated that HP‐DM1 mAb blocked KIR2DL1 recognition of C2+ HLA‐C. Altogether, the data support that HP‐DM1 is a unique reagent valuable for characterizing KIR+ NK cell subsets.

4 April 2023
Verified
Other
Open access
MCMariona Cabo
Mariona Cabo
SSSara Santana-Hernández
Sara Santana-Hernández
MCMarcel Costa-Garcia
Marcel Costa-Garcia
ARAnna Rea
Anna Rea
RLRoberto Lozano-Rodríguez
Roberto Lozano-Rodríguez
AMAura Muntasell
Aura Muntasell
Figures S1, S2, S3, S4, S5, S6

4 April 2023
Verified
Other
Open access
MCMariona Cabo
Mariona Cabo
SSSara Santana-Hernández
Sara Santana-Hernández
MCMarcel Costa-Garcia
Marcel Costa-Garcia
ARAnna Rea
Anna Rea
RLRoberto Lozano-Rodríguez
Roberto Lozano-Rodríguez
AMAura Muntasell
Aura Muntasell
Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the anti-CD137 agonist urelumab can overcome TGFβ-mediated inhibition of human NK-cell proliferation and antitumor function. Transcriptomic, immunophenotypic, and functional analyses showed that CD137 costimulation modified the transcriptional program induced by TGFβ on human NK cells by rescuing their proliferation in response to IL2, preserving their expression of activating receptors (NKG2D) and effector molecules (granzyme B, IFNγ) while allowing the acquisition of tumor-homing/retention features (CXCR3, CD103). Activated NK cells cultured in the presence of TGFβ1 and CD137 agonist recovered CCL5 and IFNγ secretion and showed enhanced direct and antibody-dependent cytotoxicity upon restimulation with cancer cells. Trastuzumab treatment of fresh breast carcinoma–derived multicellular cultures induced CD137 expression on tumor-infiltrating CD16+ NK cells, enabling the action of urelumab, which fostered tumor-infiltrating NK cells and recapitulated the enhancement of CCL5 and IFNγ production. Bioinformatic analysis pointed to IFNG as the driver of the association between NK cells and clinical response to trastuzumab in patients with HER2-positive primary breast cancer, highlighting the translational relevance of the CD137 costimulatory axis for enhancing IFNγ production. Our data reveals CD137 as a targetable checkpoint for overturning TGFβ constraints on NK-cell antitumor responses.

4 April 2023
Verified
Other
Open access
MCMariona Cabo
Mariona Cabo
SSSara Santana-Hernández
Sara Santana-Hernández
MCMarcel Costa-Garcia
Marcel Costa-Garcia
ARAnna Rea
Anna Rea
RLRoberto Lozano-Rodríguez
Roberto Lozano-Rodríguez
AMAura Muntasell
Aura Muntasell